1. Academic Validation
  2. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

  • Nat Commun. 2020 Mar 27;11(1):1620. doi: 10.1038/s41467-020-15562-9.
Xiuyuan Ou  # 1 Yan Liu  # 1 Xiaobo Lei  # 1 Pei Li 1 Dan Mi 1 Lili Ren 1 Li Guo 1 Ruixuan Guo 1 Ting Chen 1 Jiaxin Hu 1 Zichun Xiang 1 Zhixia Mu 1 Xing Chen 2 Jieyong Chen 3 Keping Hu 2 Qi Jin 4 Jianwei Wang 5 Zhaohui Qian 6
Affiliations

Affiliations

  • 1 NHC Key laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, 100176, Beijing, China.
  • 2 Institute of Medicinal Plant Development (IMPLAD), Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical Collage (PUMC), 151 Malianwa Road North, Haidian District, 100193, Beijing, China.
  • 3 Hengshui Third People's Hospital, Heibei, China.
  • 4 NHC Key laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, 100176, Beijing, China. jinqi@ipbcams.ac.cn.
  • 5 NHC Key laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, 100176, Beijing, China. wangjw28@163.com.
  • 6 NHC Key laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, 100176, Beijing, China. zqian2013@sina.com.
  • # Contributed equally.
Abstract

Since 2002, beta coronaviruses (CoV) have caused three zoonotic outbreaks, SARS-CoV in 2002-2003, MERS-CoV in 2012, and the newly emerged SARS-CoV-2 in late 2019. However, little is currently known about the biology of SARS-CoV-2. Here, using SARS-CoV-2 S Protein pseudovirus system, we confirm that human angiotensin converting Enzyme 2 (hACE2) is the receptor for SARS-CoV-2, find that SARS-CoV-2 enters 293/hACE2 cells mainly through endocytosis, that PIKfyve, TPC2, and Cathepsin L are critical for entry, and that SARS-CoV-2 S Protein is less stable than SARS-CoV S. Polyclonal anti-SARS S1 Antibodies T62 inhibit entry of SARS-CoV S but not SARS-CoV-2 S pseudovirions. Further studies using recovered SARS and COVID-19 patients' sera show limited cross-neutralization, suggesting that recovery from one Infection might not protect against the other. Our results present potential targets for development of drugs and vaccines for SARS-CoV-2.

Figures
Products